Apyx Medical (NASDAQ:APYX) Stock Price Up 7.2% - Should You Buy?

Key Points

• Apyx Medical's stock price increased by 7.2% on Monday, reaching a last trade price of $3.13, despite a significant decline in trading volume.
• Wall Street analysts have a mixed outlook on Apyx Medical, with a consensus rating of "Moderate Buy" despite one analyst giving a "Strong Buy" and others issuing sell ratings.
• The company reported a quarterly revenue of $11.37 million, slightly below analysts' expectations, and is projected to have an EPS of -0.68 for the current fiscal year.

Apyx Medical Corporation (NASDAQ:APYX - Get Free Report) rose 7.2% on Monday . The stock traded as high as $3.15 and last traded at $3.13. Approximately 63,092 shares were traded during mid-day trading, a decline of 58% from the average daily volume of 149,901 shares. The stock had previously closed at $2.92.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Apyx Medical in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Apyx Medical has a consensus rating of "Moderate Buy".

Apyx Medical Stock Performance

The company has a market cap of $118.38 million, a P/E ratio of -6.96 and a beta of 1.46. The firm has a 50 day moving average of $2.29 and a 200-day moving average of $1.88. The company has a quick ratio of 3.95, a current ratio of 4.72 and a debt-to-equity ratio of 4.61.

Apyx Medical (NASDAQ:APYX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). Apyx Medical had a negative return on equity of 158.22% and a negative net margin of 37.11%.The company had revenue of $11.37 million for the quarter, compared to analysts' expectations of $11.69 million. Apyx Medical has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Apyx Medical Corporation will post -0.68 EPS for the current fiscal year.

Institutional Trading of Apyx Medical

Several hedge funds and other institutional investors have recently bought and sold shares of APYX. Joel Isaacson & Co. LLC bought a new stake in Apyx Medical during the 1st quarter valued at $28,000. Kingsview Wealth Management LLC boosted its position in Apyx Medical by 29.5% during the 1st quarter. Kingsview Wealth Management LLC now owns 175,095 shares of the company's stock valued at $240,000 after acquiring an additional 39,850 shares in the last quarter. Nantahala Capital Management LLC boosted its position in Apyx Medical by 2.8% during the 1st quarter. Nantahala Capital Management LLC now owns 3,258,048 shares of the company's stock valued at $4,464,000 after acquiring an additional 88,248 shares in the last quarter. Silverberg Bernstein Capital Management LLC boosted its position in Apyx Medical by 38.7% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 896,736 shares of the company's stock valued at $2,018,000 after acquiring an additional 250,167 shares in the last quarter. Finally, Fisher Asset Management LLC bought a new stake in Apyx Medical during the 2nd quarter valued at $34,000. Institutional investors own 55.33% of the company's stock.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.